艾曲泊帕长期治疗慢性/持续性免疫性血小板减少症的安全性和疗效:EXTEND研究的最终结果
EXTEND开放标签研究评估艾曲泊帕长期治疗成人免疫性血小板减少症(ITP)的安全性和疗效,302例患者中位治疗2.37年,中位血小板计数在第2周升至≥50×10⁹/L并维持,85.8%患者获得缓解,出血症状从基线57%降至1年时16%,14%因不良事件退出,血栓栓塞(6%)和肝胆不良事件(15%)发生率在治疗超过1年后未增加。
要点
- 艾曲泊帕长期治疗使中位血小板计数在第2周升至≥50×10⁹/L并维持整个治疗期。
- 85.8%患者获得缓解,52%患者获得持续25周以上的持续缓解。
- 出血症状(WHO 1-4级)从基线57%降至1年时16%。
核心结论
- EXTEND研究表明,长期使用艾曲泊帕可有效维持大多数病程超过6个月的ITP患者的血小板计数≥50×10⁹/L并减少出血。
- 重要不良事件(如血栓形成、肝胆事件和骨髓纤维化)不常见。
研究设计与样本
- 开放标签EXTEND研究纳入已完成既往艾曲泊帕研究的成人ITP患者302例。
- 艾曲泊帕中位治疗时间为2.37年(范围2天至8.76年)。
主要发现
- 中位血小板计数在第2周升至≥50×10⁹/L,并在整个治疗期间维持。
- 259例(85.8%)患者获得缓解(无救援治疗情况下至少一次血小板计数≥50×10⁹/L),257例中133例(52%)获得持续25周以上的持续缓解。
- 血小板计数低于15×10⁹/L、既往治疗更多和/或脾切除的患者缓解率略低。
- 101例接受伴随ITP药物治疗的患者中34例(34%)停用1种或以上药物。
- 在有评估的患者中,出血症状(世界卫生组织1-4级)从基线57%降至1年时16%。
关键数值与推荐
- 41例(14%)患者因不良事件退出。
- 肝胆不良事件(n=7)、白内障(n=4)、深静脉血栓(n=3)、脑梗死(n=2)、头痛(n=2)和骨髓纤维化(n=2)发生在超过1例患者中,其余不良事件仅发生1次。
- 血栓栓塞事件发生率6%,肝胆不良事件发生率15%,在治疗超过1年后未增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding. The open-label EXTEND study evaluated long-term safety and efficacy of eltrombopag in adults with ITP who had completed a previous eltrombopag study. For the 302 patients enrolled, median duration of eltrombopag treatment was 2.37 years (2 days-8.76 years). Median platelet counts increased to 50 × 109/L or more by week 2 and were sustained throughout the treatment period. Overall, 259 patients (85.8%) achieved a response (platelet count ≥50 × 109/L at least once in the absence of rescue), and 133 (52%) of 257 patients achieved a continuous response of 25 weeks or longer. Responses in patients with platelet counts lower than 15 × 109/L, more previous therapies, and/or splenectomy were somewhat lower. Thirty-four (34%) of 101 patients receiving concomitant ITP medication discontinued 1 or more medication. In patients with assessments, bleeding symptoms (World Health Organization grades 1-4) decreased from 57% at baseline to 16% at 1 year. Forty-one patients (14%) withdrew because of adverse events. Hepatobiliary adverse events (n = 7), cataracts (n = 4), deep vein thrombosis (n = 3), cerebral infarction (n = 2), headache (n = 2), and myelofibrosis (n = 2) occurred in more than 1 patient; the remaining adverse events occurred only once. Rates of thromboembolic events (6%) and hepatobiliary adverse events (15%) did not increase with treatment duration past 1 year. EXTEND demonstrated that long-term use of eltrombopag was effective in maintaining platelet counts of 50 × 109/L or more and reducing bleeding in most patients with ITP of more than 6 months' duration. Important adverse events (eg, thrombosis, hepatobiliary, and bone marrow fibrosis) were infrequent. (ClinicalTrials.gov:NCT00351468).
引用
- Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017. PMID: 29042367. doi:10.1182/blood-2017-04-748707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。